AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 221 min read$AMGN

Amgen posts trial win for Sjögren's disease drug (AMGN:NASDAQ)

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep, a treatment for Sjögren's disease, and shares rose in premarket trading. The company cited topline data as the basis for the positive outcome.

Original reporting
seekingalpha.com
Published Sep 22, 2026, 1:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 2:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The trial win provides a clear catalyst for AMGN, likely prompting buying pressure.

02

Market read

First report of pivotal trial success for a major biotech; immediate price impact expected.

03

What to watch

Potential competition from other Sjögren's therapies and reimbursement uncertainties.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Amgen's dazodalibep is an experimental therapy targeting Sjögren's disease, an autoimmune condition with unmet need.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen announced a Phase 3 trial win for its Sjögren's disease drug dazodalibep, driving pre‑market price rise.

Expected impact

upward move in near‑term trading

Evidence & confidence

First disclosure of pivotal trial success for a large‑cap biotech; market typically reacts strongly to such news.

Market effects

Sector

Biotech sector may see broader rally on positive autoimmune trial data.

Regional

U.S. biotech stocks likely to benefit.

Global

Limited to pharma/biotech investors worldwide.

Counterpoint

What could challenge this read

If data does not translate into regulatory approval, the rally could be short‑lived.

Key entities

  • company
    Amgen Inc.

    Biopharma company reporting the trial result.

  • product
    dazodalibep

    Experimental drug for Sjögren's disease.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 22
$AMGNMedAI 9/10

Amgen’s dazodalibep meets primary endpoint in Sjögren’s trial

Amgen (AMGN) reported that its Phase 3 trial of dazodalibep met the primary endpoint in treating Sjögren’s disease, showing significant improvement at Week 48. The study enrolled 621 patients. Dazodalibep is not yet FDA-approved. Amgen plans to share detailed data at a future medical meeting. The company's Phase 3 OASIZ 303 study is expected to complete in Q4 2026.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Why is Amgen stock surging today?

Amgen (AMGN) stock rose 3.5% after its Phase 3 OASIZ 301 study of dazodalibep met primary endpoints, showing improvement in systemic Sjögren’s disease. Analysts maintained varied ratings. The broader market saw modest gains.

investing.com2 min
SEP 22
$AMGNHighAI 8/10

Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle

Amgen (AMGN) reported that its Phase 3 trial for dazodalibep met its primary endpoint in treating moderate-to-severe systemic Sjögren’s disease, showing statistically significant improvement. The study enrolled 651 participants, and the drug is currently under review. Amgen's revenue was $10.054 billion in Q2 2026, with net income of $2.375 billion. A second Phase 3 trial, OASIZ 303, is expected to complete in Q4 2026.

financial-news.co.uk2 min
SEP 22
$AMGNHighAI 8/10

Amgen stock surges on positive Sjögren’s trial results

Amgen Inc (AMGN) shares rose 4% premarket after positive Phase 3 trial results for dazodalibep in treating Sjögren’s disease. The study met its primary endpoint, showing significant improvement in disease activity. Sjögren’s has no FDA-approved treatments. Adverse events were mild to moderate. Amgen plans to present detailed data at a future medical meeting.

investing.com2 min
SEP 22
$AMGNMedAI 8/10

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Amgen (AMGN) reported positive Phase 3 results for dazodalibep in treating moderate-to-severe Sjögren's disease. The study met its primary endpoint, showing significant improvement in disease activity. Dazodalibep is a potential first-in-class treatment with no current FDA-approved options for this condition. Amgen plans to present detailed data at an upcoming medical meeting.

prnewswire.com2 min